2026.05.29 G2G Bio(456160) Korea Stock Analysis - Neutral
📌 Company Overview G2G Bio (지투지바이오, Ticker: 456160) is a South Korean biopharmaceutical company listed on the KOSPI market, headquartered in Cheongju, North Chungcheong Province (Osong Medical Innovation District). Founded in March 2017 and led by CEO Lee Hee-yong, the company is a pre-revenue-stage R&D-driven biotech focused on next-generation long-acting drug formulation technology . Its core proprietary platform is "InnuLAMP" — a monthly sustained-release delivery system designed for obesity drugs including cagrilintide, tirzepatide, and retatrutide analogues. The company gained significant investor attention following its 2025 IPO and has been actively courting partnerships with global Big Pharma players such as Eli Lilly and Samsung Bioepis. 📈 Current Stock Price Current Price: ₩58,200 | Change: -₩4,600 (-7.32%) Volume: 250,061 shares | 52-Week High: ₩124,000 | 52-Week Low: ₩27,581 (As of 2026-05-29 16:25 KST, market close) ...